131214-20-5Relevant articles and documents
Palladium-Catalyzed Fluorosulfonylvinylation of Organic Iodides
Zha, Gao-Feng,Zheng, Qinheng,Leng, Jing,Wu, Peng,Qin, Hua-Li,Sharpless, K. Barry
, p. 4849 - 4852 (2017)
A palladium-catalyzed fluorosulfonylvinylation reaction of organic iodides is described. Catalytic Pd(OAc)2 with a stoichiometric amount of silver(I) trifluoroacetate enables the coupling process between either an (hetero)aryl or alkenyl iodide with ethenesulfonyl fluoride (ESF). The method is demonstrated in the successful syntheses of eighty-eight otherwise difficult to access compounds, in up to 99 % yields, including the unprecedented 2-heteroarylethenesulfonyl fluorides and 1,3-dienylsulfonyl fluorides.
Higuchi,Kristiansen
, p. 1601,1604 (1970)
Effect of molecular conformation on interaction of organic species in water. Benzamides and anisamides with theophylline and riboflavin.
Nakano,Higuchi
, p. 183 - 184 (1968)
-
Manganese Catalyzed Enantioselective Epoxidation of α,β-Unsaturated Amides with H2O2
Ottenbacher, Roman V.,Kurganskiy, Vladimir I.,Talsi, Evgenii P.,Bryliakov, Konstantin P.
, p. 2778 - 2782 (2021/04/29)
Herewith, we report the enantioselective epoxidation of electron-deficient cis- and trans-α,β-unsaturated amides with the environmentally benign oxidant H2O2. The catalysts - manganese complexes with bis-amino-bis-pyridine and structurally related ligands - exhibit reasonably high efficiency (up to 100 TON) and excellent chemo- and enantioselectivity (up to 100% and 99% ee, respectively). Crucially, the cis-enamides epoxidation enantioselectivity and yield are dramatically enhanced by the presence of NH-moiety, which effect can be explained by the hydrogen bonding interaction between the cis-enamide substrate and the manganese based oxygen transferring species. (Figure presented.).
LIPOXYGENASE INHIBITORS
-
Paragraph 00601-00603, (2021/10/02)
Various embodiments of the present disclosure are directed to compounds having Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases, and/or treating associated diseases, such as Alzheimer's disease. In some embodiments, the compounds may be administered to a patient as part of a pharmaceutical formulation.